NasdaqHealth CareBiological Products, (No Diagnostic Substances)CAMBRIDGE, MA

Hemab Therapeutics Holdings, Inc. COAG

Ask your AI

Estimated market cap $1.91B46.73M shares, shares as of Oct 30, 2026CIK 2114044

Insider trades, 12 mo

16 buys · 0 sells

$55.46M bought, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

33.5% of shares · 13 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Hemab Therapeutics Holdings, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 10, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Hemab Therapeutics Holdings, Inc.'s latest quarterly report, compared with the one before.

Loading…

IPO prospectus

Priced

Hemab Therapeutics Holdings, Inc.’s initial public offering: where it stands and what the registration statement says.

Priced · Proposed ticker COAG, Nasdaq Global Select Market · First filed Apr 10, 2026 · Priced May 1, 2026

Raised

$301.5M

price times shares, before any over-allotment

Price per share

$18.00

on the final prospectus

Shares offered

16.75M

base offering

Read from the S-1/A filed Apr 30, 2026 · Read it on sec.gov ↗

Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
Summary text goes here once it has loaded. Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
Summary text goes here once it has loaded.

AI summary of the prospectus. Written by AI from the parts of the prospectus listed in the filing, and checked against its text. This is information, not investment advice.

All filings of this IPO Read the S-1/A on sec.gov ↗

IPO prospectus

Hemab Therapeutics Holdings, Inc.’s initial public offering: where it stands and what the registration statement says.

Loading…

Insider trades

16 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Jun 16, 2026. Insiders have two business days to file.

Recent insider trades

Ra Capital Management, L.P. 10% owner	Jun 16 Form 4 ↗	Buy	+$1.5M 61,523 sh @ $24.98	+59.6%
Ra Capital Management, L.P. 10% owner	Jun 15 Form 4 ↗	Buy	+$153.0K 6,146 sh @ $24.89	+63.0%
Ra Capital Management, L.P. 10% owner	May 20 Form 4 ↗	Buy	+$24.8K 996 sh @ $24.94	+52.6%
Ra Capital Management, L.P. 10% owner	May 19 Form 4 ↗	Buy	+$94.9K 3,802 sh @ $24.97	+57.8%
Peter Kolchinsky 10% owner	May 12 Form 4 ↗	Buy	+$159.0K 6,387 sh @ $24.90	+55.6%

All COAG insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

15.64M shares

48 funds report COAG. Values checked against market prices.

Funds own 77% of shares (Q2 2026)

55 funds hold the stock.

Q3 2026: 33% · 5,560 of ~8,900 funds reported so far

Q2 202677%
Q3 2026 (so far)33%

Q3 2026. 27 new, 13 added to, 6 trimmed, 34 exited since Q2 2026.

Top 13F holders
#
1	FMR LLC 13F ↗	3.72M	$114.8M	+0.7%
2	Capital International Investors 13F ↗	3.60M	$111.1M	-0.1%
3	Siren, LLC 13F ↗	2.37M	$73.0M	+13.4%
4	BlackRock, Inc. 13F ↗	1.40M	$43.1M	+392.9%
5	JPMorgan Chase & Co 13F ↗	932,857	$30.4M	-19.1%
6	State Street Corp 13F ↗	927,245	$28.6M	New
7	Vanguard Capital Management LLC 13F ↗	774,064	$23.9M	-0.9%
8	Geode Capital Management, LLC 13F ↗	502,042	$15.5M	+137.0%
9	Affinity Asset Advisors, LLC 13F ↗	420,000	$13.0M	+204.3%
10	Vanguard Portfolio Management LLC 13F ↗	137,143	$4.2M	+1578.8%

Download CSV Every fund that holds COAG, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Hemab Therapeutics Holdings, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Hemab Therapeutics Holdings, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q2 2026	55	—	36.18M	$1.3B
Q3 2026	48	-7	15.64M	$484.2M

Each point is a quarter-end, from Q2 2026 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (423494103). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2026) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes10 in 12 mo 8-K events2 in 90 days Patents1 patent granted Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record IPO history1 registration Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Hemab Therapeutics Holdings, Inc.
Address: 101 MAIN STREET, SUITE 1220, CAMBRIDGE, MA 02142
Phone: 45 2138 7627
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company, emerging growth company
Incorporated in: DE
Listed as: COAG (Nasdaq)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$40.86+$1.48 (+3.76%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $29.80 · High $49.02Nov 13, 2026

Aug 13, 2026Low $28.37 · High $54.94Nov 13, 2026

May 1, 2026Low $24.98 · High $54.94Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.